SecBot SecBot
DEF 14A ·Filed Oct 29, 2026

VASO

VASO Corp
NEUTRAL
Impact 2/10
Horizondays Processed3d 5h ago SEC0001213900-26-113710
Definitive proxy statement
Actionable Insight • Neutral

Monitor the December 8 meeting for any unexpected proposals or voting outcomes. The proxy is routine with no contested items, so no near-term trading catalyst is expected.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled: T+1d ⚠ clustered
VASO ▲ 0.00% at T+1d
NEUTRAL call 0.00% · α vs SPY +1.77% · entry $0.2900 → $0.2900
Next anchor: T+5d in 4d
Entry = T+0 close
Oct 29, 2026
via day close
T+1d
0.00%
call 0.00% · α +1.77%
$0.2900
settled 2d ago
T+5d
Pending
in 4d
T+20d
Pending
in 26d
T+60d
Pending
in 3mo

Price Chart

Loading chart...

Executive Summary

Vaso Corp's 2026 definitive proxy statement schedules an annual meeting for December 8, 2026, with the sole agenda item being the election of two Class III directors (Jun Ma and Shaun McMeans). The filing is routine: no shareholder proposals, no say-on-pay vote, no related party transactions above the reporting threshold, and no governance changes. Executive compensation increased year-over-year for the CEO and CFO, while net income rose to $1.569 million in 2025 from $951,000 in 2024.

Key Facts

  • Annual meeting scheduled for December 8, 2026; record date October 14, 2026.
  • 176,238,224 shares outstanding as of record date.
  • Two Class III director nominees: Jun Ma (incumbent CEO) and Shaun McMeans (appointed July 2026).
  • David Lieberman not standing for reelection; board size reduced from 8 to 7.
  • Officers and directors beneficially own 42.06% of voting power and intend to vote FOR the nominees.
  • No shareholder proposals, say-on-pay vote, or governance changes on the ballot.
  • No reportable related party transactions.
  • CEO Jun Ma total compensation: $807,485 in 2025 (up from $756,635 in 2024).
  • CFO Jonathan Newton total compensation: $418,450 in 2025 (up from $377,136 in 2024).
  • Net income: $1,569,000 in 2025 vs $951,000 in 2024.
  • TSR: $100 investment valued at $100 at end of 2025, down from $182 at end of 2023.
  • Auditor: UHY LLP; audit fees $292,775 in 2025.

Financial Impact

No material financial impact from this proxy filing. CEO total compensation $807,485, CFO $418,450; net income $1,569,000.

Risk Factors

  • No shareholder proposals or governance changes; low engagement risk.
  • Director Shaun McMeans previously served as CFO of HTG Molecular Diagnostics, which filed for Chapter 11 bankruptcy in 2023 and converted to Chapter 7 liquidation in 2025.
  • TSR declined significantly from $182 (2023) to $100 (2025) despite rising net income.

Market Snapshot

Exchange
OTC
Sector
Electromedical & Electrotherapeutic Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001213900-26-113710
Document: 0001213900-26-113710-index-headers.html0001213900-26-113710
Document: 0001213900-26-113710-index.html0001213900-26-113710
Document: 0001213900-26-113710.txt0001213900-26-113710
3 reports for VASO
Performance horizon
Filters
Rows
Reports for VASO, sortable and filterable
TypeNow
Oct 29, 2026
3d ago
DEFA14A
NEUTRAL ★ 2/10
$0.2900awaiting T+20awaiting T+20$0.2900 (−0.00%)
Oct 29, 2026
3d ago
DEF 14A
NEUTRAL ★ 2/10
$0.2900awaiting T+20awaiting T+20$0.2900 (−0.00%)
May 8, 2026
25w ago
8-K
NEUTRAL ★ 2/10
$0.2000 $0.1900▼ −5.00%▼ −4.70%$0.2900 (+45.00%)
Showing 3 of 3

US Market Status

Market Closed · Opens Mon (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 29, 2026